Abstract decorative geometric graphic used as a design element.

Join us at ASCO 2026

Decipher Prostate Genomic Classifier and Decipher Bladder Genomic Classifier

Booth 13069

Featured Presentation

Assessment of the ability of Decipher Prostate Genomic Classifier (GC) >0.85 to identify patients who benefit from adding docetaxel to Androgen Deprivation Therapy (ADT) plus enzalutamide: Level 1B evidence from the ENZAMET study.

Saturday, May 30th | 1:15 PM CDT
Oral | Abstract #5001 – Hall D1

Christopher Sweeney, M.B.B.S.

All Urology Featured Presentations & Posters
TitleTypeDateTimeAuthorLocationTechnology
Assessment of the ability of Decipher Prostate Genomic Classifier (GC) >0.85 to identify patients who benefit from adding docetaxel to Androgen Deprivation Therapy (ADT) plus enzalutamide: Level 1B evidence from the ENZAMET study.
Oral |
Abstract #5001
Saturday,
May 30
3:12 PM – 3:24 PM CDT
Christopher Sweeney, M.B.B.S.
Hall D1
Decipher Prostate

Clinico-transcriptomic risk stratification to guide abiraterone treatment intensification in high-risk prostate cancer: A combined analysis of NRG/RTOG 9202, 9413, 9902, and 0521
Oral |
Abstract #5000
Saturday,
May 30
3:00 PM – 3:12 PM CDT
Krishnan R. Patel, M.D.
Hall D1
Decipher Prostate
Practice patterns and outcomes by genomic risk in octogenarians with high-risk localized prostate cancer: a national real-world data analysis

Abstract #1660 |
Poster bd #578
Saturday,
May 30
9:00 AM – 12:00 PM CDT
James Janopaul-Naylor, M.D.
Hall A
Decipher Prostate GRID
Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: Final results and biomarker analyses of the SURE-01 trial
Abstract #4619 |
Poster bd #98
Sunday,
May 31
9:00 AM – 12:00 PM CDT
Brigida A. Maiorano, M.D., Ph.D.
Hall A
Decipher Bladder

Assessing the clinical and biological associations between artera Multimodal Artificial Intelligence (MMAI) and Decipher Genomic Classifier (GC) in Localized Prostate Cancer (PCa)
Abstract #5114 |
Poster bd #209
Sunday,
May 31
9:00 AM – 12:00 PM CDT
Boon Hao Hong, M.S.
Hall A
Decipher Prostate
Molecular characterization of residual disease post-neoadjuvant sacituzumab govitecan (SG), pembrolizumab, or their combination in patients with muscle-invasive bladder cancer (MIBC)
Abstract #4617 |
Poster bd #96
Sunday,
May 31
9:00 AM – 12:00 PM CDT
Andrea Necchi, M.D.
Hall A
Decipher Bladder
Genomic classifier–driven NCCN risk reclassification to track distinct transcriptomic signatures in early prostate cancer.
Rapid Oral |
Abstract #5013
Sunday,
May 31
4:36 PM – 4:42 PM CDT
Daniel Keizman, M.D.
Hall D1
Decipher Prostate

Explore Decipher

Decipher Prostate Genomic Classifier

Informing key clinical decisions across the prostate cancer continuum.

Learn More

Decipher Bladder Genomic Classifier

Biologic insights for bladder cancer.

Learn More

Scientific Publications

Publications highlighting Decipher Prostate and Decipher Bladder discoveries, clinical evidence, and advancements in prostate cancer care.

Explore

Decipher Resource Center

View scientific publications, videos, FAQS, and more.

Explore

Connect with us

Meet With Our Team

Disclaimers

Decipher testing is available in the United States as part of Veracyte’s CLIA-validated laboratory developed test (LDT) service, and FDA clearance is not required.

Talk to your doctor about whether Veracyte tests might be right for you.